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Impaired vascular reactivity in sepsis – a systematic 
review with meta-analysis
Sigita Kazune1, Anda Piebalga2, Eva Strike1, Indulis Vanags1
A b s t r a c t 
Introduction: Vascular dysfunction due to reduced nitric oxide bioavailabil-
ity plays an important role in the pathogenesis of sepsis. This meta-analy-
sis examines evidence from published literature to evaluate whether in the 
adult population the presence/severity of sepsis is associated with impaired 
vasoreactivity.
Material and methods: We performed a search of the Medline, Scopus, and 
EMBASE databases to identify observational studies using measurement 
of reactive hyperaemia in adult patients with sepsis. After data extraction 
using predefined protocol, qualitative synthesis of findings was performed 
regarding consistency of findings between methods, evidence of association 
between vascular reactivity and severity of sepsis, multiple organ failure, 
and death. A meta-analyses of standardised mean differences in vasore-
activity between groups was performed, in which data were available for 
relevant outcomes.
Results: Eighteen studies using four methods to measure vascular reactivity 
from a total of 466 were included in the analysis. The pooled standardised 
mean difference estimate showed that septic patients had less reactive hy-
peraemia than controls (–2.59, 95% CI: –3.46 to –1.72; p < 0.00001), and 
peak hyperaemic blood flow was lower in patients with sepsis than in the 
control group (SMD = –1.42, 95% CI: –2.14 to –0.70; p = 0.0001). The com-
bined SMD between non survivors and survivors was –0.36 (95% CI: –0.67 to 
–0.06; p = 0.02) for reactive hyperaemia and –0.70 (95% CI: –1.13 to –0.27; 
p = 0.001) for peak hyperaemic blood flow.
Conclusions: Septic patients have attenuated vascular reactivity when com-
pared to healthy volunteers. There are insufficient data indicating that these 
changes can identify patients at risk of worsening organ failure or death.
Key words: sepsis, meta-analysis, reactive hyperaemia.
Introduction
Vascular endothelium is thought to be the key organ involved in the 
pathogenesis of host response in sepsis [1, 2]. Quantification of endo-
thelial dysfunction may be useful in assessing the potential for devel-
opment of microvascular perfusion abnormalities and associated organ 
dysfunction.
One of the main functions of vascular endothelium is control of arteri-
al tone. Activation of endothelium in sepsis is an adaptive response to li-
popolysaccharides and cytokines, which leads to altered vasomotor tone 
and increased blood flow to infected areas [3, 4]. Activation of vascular 
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endothelium may also trigger altered haemody-
namic response and microvascular perfusion ab-
normalities [5].
Several narrative reviews [1, 4, 6] reported the 
effects of sepsis on endothelial function, and one 
systematic review [7] focused on biomarkers of 
endothelial activation in sepsis. Measurement of 
reactive hyperaemia to ischaemic or pharmaco-
logical stimuli, which serves as a test of endothe-
lial nitric oxide (NO) bioavailability, may be used 
to quantify endothelial dysfunction [8]. Different 
stimuli and measurement methodologies have 
been employed to investigate endothelial func-
tion in patients with sepsis with variable results. 
However, measurement of reactive hyperaemia 
in sepsis remains a research tool, and association 
between altered vascular reactivity and severity 
of sepsis with respect to development of multiple 
organ failure and mortality is not well established.
The objective of this study was to conduct 
a systematic review and meta-analysis of the cur-
rently published literature to provide a summary 
of existing research and evaluate whether in the 
adult population the presence/severity of sepsis is 
associated with conduit artery and microvascular 
dysfunction as measured by provocation tests. 
Material and methods
This systematic review follows recommenda-
tions of the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) state-
ment [9]. The study was registered at PROSPERO 
(CRD42018107129). We included English lan-
guage publications that met the following inclu-
sion criteria: included adult patients (18 years old 
or over) who were diagnosed with sepsis, severe 
sepsis, or septic shock, reported measurements 
of endothelial vascular reactivity by a validated 
methodology utilising standardised protocols, and 
incorporated clinical end-points. Primary outcome 
was changes of endothelial vascular reactivity in 
relation to the presence or severity of sepsis. Sec-
ondary outcomes were development or severity of 
single or multiple organ failure and intensive care 
unit, hospital, or 28-day mortality (whichever was 
available). Studies were excluded if they reported 
only blood biomarker measurements of endothe-
lial function, included paediatric patients, or were 
duplicated.
The Medline, Scopus, and EMBASE records from 
January 1985 to November 2018 were searched to 
identify relevant studies. A preliminary search us-
ing the terms “endothelium” or “endothelial func-
tion” in combination with “vascular reactivity”, 
“blood vessel reactivity”, “vascular dysfunction”, 
“vascular occlusion test”, or “reactive hyperaemia/
hyperaemia” was carried out to identify validated 
methods for assessment of endothelial function. 
Final search terms included “venous occlusion 
plethysmography”, “flow-mediated dilation”, “pe-
ripheral arterial tonometry”, “laser Doppler flow-
metry”, “pulse wave velocity”, and “augmentation 
index”, combined with “sepsis”, “septicaemia/
septicemia” or “systemic inflammatory response 
syndrome”. Filters were used to restrict results to 
human studies and English language publications. 
References from selected studies were checked to 
identify any additional articles.
Two researchers independently screened titles 
and abstracts of all articles retrieved by the search 
and then examined the full text of the relevant 
articles for fulfilment of inclusion criteria.
The following data were extracted independent-
ly by two researchers: study design, sample size, 
case mix descriptors (age, comorbidities), sepsis 
definition used, method, protocol and timing of 
vasoreactivity evaluation, use of blood-derived 
markers of endothelial function, group differences 
in reactive hyperaemia and peak hyperaemic flow 
related to any clinical outcome (presence or ab-
sence of sepsis, single or multiple organ dysfunc-
tion, severity of sepsis, mortality), and possible 
confounders. The definition of sepsis was used as 
given in the retrieved articles. Risk of random error 
in vasoreactivity measurement was assessed by 
patient sample size and reported confidence inter-
vals. To perform risk of bias assessment for this 
systematic review we adapted the Newcastle-Ot-
tawa scale for case-control studies [10]. This scale 
evaluates the risk of bias based on group selec-
tion, comparability, and assessment of outcome. 
The risk of bias assessment using the customised 
scale was done by two researchers independently.
Meta-analyses were performed using Review 
Manager software (Version 5.3; Cochrane Com-
munity). For data reported as median and inter-
quartile range, mean and 95% confidence interval 
or, provided for two septic subgroups, mean and 
standard deviation were estimated using meth-
ods described in the Cochrane Handbook for Sys-
tematic Reviews [11]. Because vasoreactivity was 
measured using several different methods, stud-
ies were summarised using standardised mean 
differences (SMD) of the mean of reactive hyper-
aemia/peak hyperaemic flow between groups for 
each relevant clinical outcome. Pooled SMD and 
95% confidence interval (CI) for each measure of 
vasoreactivity and outcome were obtained using 
a random effects model for continuous outcomes 
[12]. Pooled SMD was considered significant if 
p < 0.05. Heterogeneity was assessed using Hig-
gins I2 test [13]. Significant heterogeneity was as-
sumed if the I2 statistic was greater than or equal 
to 75%.
Planned subgroups to be analysed for hetero-
geneity included different methods of vasoreactiv-
ity assessment and studies using controls at risk 
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of endothelial dysfunction. We performed leave-
one-out sensitivity analyses by removing one 
study at a time and recalculating SMD between 
groups to confirm that our results were not influ-
enced by a single study.
Assessment of publication bias was done by 
visual assessment of funnel plots for asymmetry. 
Begg’s rank correlation and Egger’s linear regres-
sion test were used for quantitative assessment of 
funnel plots for outcomes containing ≥ 10 studies.
Results
Results of the Medline, EMBASE, and Scopus 
searches and study selection process are shown 
in Figure 1. A total of 18 observational studies 
met the inclusion criteria [14–30]. The design and 
characteristics of the included studies are shown 
in Table I. Most of the studies had medium to high 
risk of bias, as presented in Table II.
Sepsis criteria used for participant selection de-
pended on the year of the study, with the majority 
of studies using the ACCP/SCCM 1992 Consensus 
Conference definition [31]. Four studies recruited 
patients with the whole spectrum of sepsis, one 
study collected data from patients who fulfilled 
sepsis criteria but did not have organ dysfunction 
at enrolment, four studies enrolled only patients 
with septic shock, and nine studies were carried 
out on a mixed group of patients with severe sep-
sis and septic shock. The greatest number of stud-
ies (12 studies) compared septic patients with 
healthy volunteers. Other comparison groups in-
cluded intensive care or hospital patients without 
inflammation (two studies), patients after cardiac 
surgery (two studies), and intensive care patients 
with cardiogenic shock (one study). The median 
patient age in studies varied from 41 to 72 years, 
with most patients being in their 50s. There was 
variation in the proportion of male patients from 
24% to 83%, but gender was not always reported. 
In eight studies the comparison group was age 
and gender matched to the study group. 
Only in six studies were significant comorbid-
ities (cardiovascular disease, diabetes) affecting 
vascular function accounted for in the design 
and analysis of data. In another four studies pa-
tients with cardiovascular comorbidity (cardio-
genic shock or after cardiac or vascular surgery) 
were used as a comparison group. There was high 
risk of confounding because in most studies the 
groups differed significantly regarding the extent 
of vasopressor use, sedation, and mechanical ven-
tilation. Two studies included patients receiving 
nitrates and activated protein C, which are known 
to influence vascular reactivity measurements.
Methods of evaluation of vascular reactivi-
ty were venous occlusion plethysmography with 
pharmacological or ischaemic provocation, laser 
Doppler flowmetry using iontophoretically applied 
or ischaemic provocation, flow-mediated brachial 
artery vasodilatation measured by ultrasound and 
passive leg movement and peripheral arterial to-
nometry (RH-PAT) to obtain the reactive hyperae-
mia index. One study used more than one method 
to assess vascular reactivity. Timing of measure-
ments was reported in 10 studies, with seven 
Figure 1. Flow diagram of search process and study selection
Records screened after duplicates 
removed (n = 318) 
Title and abstract screening according 
to selection criteria (n = 318)
Full-text articles assessed for  
eligibility (n = 36) 
18 studies included in final analysis 
Non relevant studies excluded (n = 282)
Full-text articles excluded (n = 18)
•  3 used data from another included study 
•  4 had wrong patient population
•  4 did not report clinical outcome or had 
missing data 
•  7 did not use established methods of 
endothelial function measurement
Records identified through  
database search (n = 466)
PubMed (n = 55), Scopus (n = 216),  
EMBASE (n = 195)
Additional records identified through 
reference lists (n = 1) 
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Table II. Summary of risk of bias assessment for the included studies
Study Representa-
tion





Young 0 0 * * ** 4
Neviere 0 0 * * ** 3
Sair 0 0 ** * ? 3
Knotzer * 0 * * * 5
Kubli 0 0 * ** ** 5
Favory 0 0 * ? ** 3
Bourcier * * * 0 ** 5
Hartl 0 0 ** ? ** 4
Astiz, 1991 0 0 * * ** 4
Astiz, 1995 0 0 ** 0 ** 4
Kirschenbaum 0 0 ** * ** 5
Vaudo ? * * * ** 5
Becker * * * * ** 6
Wexler * * * ** ** 7
Nelson * 0 * ** ** 6
Davis * * * ** ** 7
van Ierssel * 0 * * ** 5
Nobre * * * ? ** 5
One star (*) per category was awarded if sample was representative of the average septic population, sample size was justified and 
satisfactory, measurement was made with a previously described method, the subjects in different outcome groups were age and gender 
matched; two stars (**) were awarded for studies that used a gold standard measurement method, controlled for confounding, and 
assessed outcome reliably; ?, data not available.
studies performing initial measurement within 
24 h of ICU admission or sepsis diagnosis. Eight 
studies used longitudinal measurements of vascu-
lar reactivity performed 24 to 48 h apart.
The number of patients included in individual 
studies was small and exceeded 30 in only five 
studies. Confidence intervals of vasoreactivi-
ty measurements were reported in four studies. 
Overall risk of random error was therefore judged 
as high. In only two studies, both using peripheral 
arterial tonometry, was the precision of reactive 
hyperaemia estimate high.
There were sufficient data in the included stud-
ies for statistical pooling for two outcomes, SMD 
in vasoreactivity between septic patients and con-
trols, and between survivors and non survivors. 
Measurements of absolute (peak flow) and rela-
tive (reactive hyperaemia) change of blood flow 
or artery diameter after provocation were pooled 
separately.
Data from 14 studies were included in the anal-
ysis of mean difference in vasoreactivity measure-
ments between septic patients and controls. The 
pooled mean difference estimate from 10 studies 
including 554 participants showed that septic pa-
tients had less reactive hyperaemia than controls 
(SMD = –2.59, 95% CI: –3.46 to –1.72; Z = 5.85, 
p < 0.00001; Figure 2). In nine studies with 354 
participants peak hyperaemic blood flow was low-
er in patients with sepsis than in the control group 
(SMD = –1.42, 95% CI: –2.14 to –0.70; Z = 3.88, 
p = 0.0001; Figure 3). The results of these studies 
were highly heterogeneous with I2 values of 92% 
(p < 0.00001) and 85% (p < 0.00001), most likely 
due to differences in study protocols and popula-
tions. After removal of any of the studies in the 
sensitivity analysis the direction of the difference 
between septic and control group did not change.
Five studies were selected to compare vasore-
activity in survivors and non survivors of sepsis. 
The combined SMD between non survivors and 
survivors was –0.36 (95% CI: –0.67 to –0.06; Z = 
2.36; p = 0.02, Figure 4) for reactive hyperaemia 
and –0.70 (95% CI: –1.13 to –0.27; Z = 3.23; p = 
0.001, Figure 5) for peak hyperaemic blood flow. 
Both reactive hyperaemia and peak hyperaemic 
flow were lower in non survivors. Tests for hetero-
geneity were statistically not significant for both 
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estimates. By removing the study by Wexler [23], 
which had the largest number of participants, sta-
tistical significance of difference in peak hyper-
aemic flow (SMD = –0.42, 95% CI: –0.93 to 0.13; 
Z = 1.5, p = 0.13) and reactive hyperaemia (SMD 
= –0.36, 95% CI: –0.73 to 0.01; Z = 1.92; p = 0.05) 
between survivors and non survivors was lost.
We pooled studies using a control group of 
patients with severe cardiovascular disease and 
therefore at high baseline risk of endothelial 
dysfunction separately. In three studies involving 
56 patients the magnitude of reactive hyperae-
mia in the septic and cardiovascular risk groups 
was similar (SMD = –2.23, 95% CI: –4.67 to 0.21; 
Z = 1.79; p = 0.07; I2 = 91%, Figure 6).
One study [16] was able to measure endothe-
lium-dependent (EDVD) and -independent vaso-
dilatation separately. No difference in EDVD was 
found between the septic and control groups.
Conflicting results were reported regarding the 
relationship between vascular reactivity measure-
ments and development of multiple organ failure 
(MOF), but the data presented were insufficient 
for pooling.
Four studies assessed the consistency of find-
ings across different methods of measurement or 
coherence with biochemical markers. Changes in 
both macrovascular reactivity measured by venous 
occlusion plethysmography and microvascular re-
activity measured by laser Doppler flowmetry were 
found in a group of severe sepsis patients by Sair 
et al. [15]. Three studies assessed coherence of de-
creased vascular reactivity with biochemical mark-
ers of endothelial activation or damage. No correla-
tion was found with levels of endothelin-1 (ET-1) 
[24], vascular cell adhesion molecule (sVCAM-1) 
[24], intercellular adhesion molecule (ICAM-1) [26], 
E selectin [26], endothelial progenitor cells (EPC) 
[27], and endothelial microparticles [27].
Visual inspection and statistical tests showed 
asymmetry of the funnel plot examining SMD of 
reactive hyperaemia in septic patients and con-
trols (Begg’s rank correlation test: p < 0.05; Egger’s 
linear regression test: p < 0.0001), suggesting pos-
sible publication bias. No evidence for publication 
bias was found for other outcomes (Figure 7).
Discussion
We summarised studies assessing vascular re-
activity in patients with sepsis and explored the 
consistency of association between impaired vas-
cular reactivity and sepsis as well as the ability of 
functional vascular reactivity tests to predict clini-
cally relevant outcomes.
In the 18 studies using established methods of 
vascular reactivity measurement included in this 
review there was convincingly lower vascular reac-
tivity in patients with sepsis compared to controls, 
Study or   Sepsis   Control  Weight   Std. mean difference    Year Std. mean difference  
subgroup Mean SD Total Mean SD Total (%) IV, random, 95% CI  IV, random, 95% CI
1.1.1. Laser Doppler flowmetry
Young 40 23 11 181 35 9 8.7 –4.66 (–6.50, –2.83) 1995  
Sair 259 72 6 1122 131 7 4.2 –7.42 (–11.00, –3.83) 2001 
Subtotal (95% CI)   17   16 12.9 –5.59 (–8.14, –3.04) 
Heterogeneity: t2 = 1.68; c2 = –1.79, df = 1 (p = 0.18), I2 = 44% 
Test for overall effect: Z = 4.30 (p < 0.0001) 
 
1.1.2. Plethysmography 
Astiz 1995 1.6 0.1 8 3.2 0.2 9 3.9 –9.42 (–13.15, –5.68) 1995 
Kirschenbaum 50 11 6 145 20 6 5.5 –5.43 (–8.32, –2.55) 2000 
Subtotal (95% CI)   14   15 9.5 –7.24 (–11.13, –3.35) 
Heterogeneity: t2 = 5.04; c2 = 2.74, df = 1 (p = 0.10), I2 = 63% 
Test for overall effect: Z = 3.65 (p = 0.0003) 
1.1.3. Brachial artery sosgraphy
Vaudo 8.7 3.6 45 9.9 1.1 25 13.7 –0.40 (–0.89, 0.09) 2008 
Becker 1.5 7 42 6 4 38 13.8 –0.77 (–1.23, –0.32) 2012 
Wexler 2.75 2.95 95 4.11 2.84 52 14.0 –0.46 (–0.81, –0.12) 2012 
Nelson 1.1 1.7 17 6.8 1.3 16 11.4 –3.66 (–4.82, –2.50) 2016 
Subtotal (95% CI)   199   131 52.9 –1.11 (–1.90, –0.32) 
Heterogeneity: t2 = 0.55; c2 = 28.13, df = 3 (p < 0.00001), I2 = 89% 
Test for overall effect: Z = 2.75 (p = 0.006) 
1.1.4. Peripheral arterial tonometry 
Davis 1.67 0.51 85 2.05 0.49 45 14.0 –0.75 (–1.12, –0.38) 2009 
Van Ierssel 1.88 0.11 20 2.41 0.14 12 10.8 –4.24 (–5.56, –2.92) 2013 
Subtotal (95% CI)   105   57 24.7 –2.44 (–5.85, 0.98) 
Heterogeneity: t2 = 5.84; c2 = 24.85, df = 1 (p < 0.00001), I2 = 96% 
Test for overall effect: Z = 1.40 (p = 0.16) 
Total (95% CI)   335   219 100.0 –2.59 (–3.46, –1.72) 
Heterogeneity: t2 = 1.37; c2 = 115.51, df = 9 (p < 0.00001), I2 = 92%
Test for overall effect: Z = 5.85 (p < 0.00001)
Test for subgroup differences: c2 = 19.06, df = 3 (p = 0.0003), I2 = 84.3%
Figure 2. Forest plots of standardised mean difference of reactive hyperaemia in septic patients and controls and 
subgroup meta-analysis of different methods of measurement
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 Favours sepsis    Favours control
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Study or   Sepsis   Control  Weight   Std. mean difference  Std. mean difference 
subgroup Mean SD Total Mean SD Total (%) IV, random, 95% CI IV, random, 95% CI
1.2.1. Laser Doppler flowmetry
Kubli 167 63 12 336 98 16 11.8 –1.93 (–2.86, –1.00) 
Favory 1.623  2.949 12 3.623 1.881 8 11.8 –0.74 (–1.67, 0.19)  
Subtotal (95% CI)   24   24 23.6 –1.34 (–2.50, –0.17) 
Heterogeneity: t2 = 0.48; c2 = 3.16, df = 1 (p = 0.08), I2 = 68%
Test for overall effect: Z = 2.25 (p = 0.02)
1.2.2. Plethysmography
Sair 4.3 1.6 6 10.6 0.9 7 5.6 –4.63 (–7.02, –2.23) 
Astiz 1991 34.63 4.32 15 51.14 3.32 10 9.2 –4.03 (–5.49, –2.58) 
Hartl 13.9 2.1 12 17.3 1.4 10 11.3 –1.80 (–2.82, –0.77) 
Astiz 1995 32 11.3 8 36 15 9 11.7 –0.28 (–1.24, 0.68) 
Kirschenbaum 50.8 6.3 6 51.2 3.6 6 10.8 –0.07 (–1.20, 1.06) 
Subtotal (95% CI)   47   42 48.5 –1.97 (–3.53, –0.41) 
Heterogeneity: t2 = 2.65; c2 = 30.60, df = 4 (p < 0.00001), I2 = 87%
Test for overall effect: Z = 2.48 (p = 0.01)
1.2.3. Brachial artery sonography 
Wexler 35.7 17 95 63.5 21.5 52 14.1 –1.48 (–1.86, –1.10) 
Vaudo 256 112 45 278 132 25 13.8 –0.18 (–0.67, 0.31) 
Subtotal (95% CI)   140   77 27.9 –0.84 (–2.11, 0.43) 
Heterogeneity: t2 = 0.79; c2 = 16.82, df = 1 (p < 0.0001), I2 = 94%
Test for overall effect: Z = 1.30 (p = 0.19)
Total (95% CI)   211   143 100.0 –1.42 (–2.14, –0.70) 
Heterogeneity: t2 = 0.91; c2 = 52.60, df = 8 (p < 0.00001), I2 = 85%
Test for overall effect: Z = 3.88 (p = 0.0001)
Test for subgroup differences: c2 = 1.22, df = 2 (p = 0.54), I2 = 0%
Figure 3. Forest plots of standardised mean difference of peak hyperaemic flow in septic patients and controls and 
subgroup meta-analysis of different methods of measurement
 –10 –5 0 5 10
 Favours sepsis    Favours control
Study or   Non survivors  Survivors  Weight   Std. mean difference   Year Std. mean difference 
subgroup Mean SD Total Mean SD Total (%) IV, random, 95% CI  IV, random, 95% CI
Knotzer 63 44 14 72 54 15 17.1 –0.18 (–0.91, 0.55) 2007 
Becker –1.4 9 14 2.9 5 28 21.1 –0.64 (–1.30, 0.02) 2012
Wexler 1.9 2.21 17 2.96 2.98 78 32.8 –0.37 (–0.89, 0.16) 2012
Nobre 1.44 0.9 17 1.62 0.56 45 29.1 –0.27 (–0.83, 0.29) 2016
Total (95% CI)   62   166 100.0 –0.36 (–0.67, –0.06)
Heterogeneity: t2 = 0.00; c2 = 1.06, df = 3 (p = 0.79), I2 = 0%
Test for overall effect: Z = 2.36 (p = 0.02)
Figure 4. Forest plots of standardised mean difference of reactive hyperaemia in survivors and non survivors of 
sepsis
 –2 –1 0 1 2
                            Favours non survivors         Favours survivors
Study or   Non survivors  Survivors  Weight   Std. mean difference   Year Std. mean difference 
subgroup Mean SD Total Mean SD Total (%) IV, random, 95% CI  IV, random, 95% CI
Knotzer 56 40 14 69 44 15 29.3 –0.30 (–1.03, 0.43) 2007  
Wexler 25 8.9 17 39 14.8 78 48.2 –0.99 (–1.54, –0.45) 2012 
Bourcier 6 3.7 8 16 19.3 18 22.5 –0.59 (–1.44, 0.26) 2017 
Total (95% CI)   39   111 100.0 –0.70 (–1.13, –0.27) 
Heterogeneity: t2 = 0.02; c2 = 2.33, df = 2 (p = 0.31), I2 = 14%
Test for overall effect: Z = 3.23 (p = 0.001)
Figure 5. Forest plots of standardised mean difference of peak hyperaemic flow in survivors and non survivors of 
sepsis
 –4 –2 0 2 4
                            Favours non survivors         Favours survivors
Study or   Sepsis         CV risk control Weight   Std. mean difference   Year Std. mean difference 
subgroup Mean SD Total Mean SD Total (%) IV, random, 95% CI  IV, random, 95% CI
Young (postCPB) 40 23 11 147 19 19 32.0 –5.07 (–6.64, –3.51) 1995
Kirschenbaum (cardio) 50 11 6 60 10 8 34.2 –0.90 (–2.03, 0.23) 2000
Sair (postCPB) 259 72 6 313 36 6 33.8 –0.88 (–2.09, 0.33) 2001
Total (95% CI)   23   33 100.0 –2.23 (–4.67, 0.21)
Heterogeneity: t2 = 4.20; c2 = 21.51, df = 2 (p < 0.0001), I2 = 91%
Test for overall effect: Z = 1.79 (p = 0.07)
Figure 6. Forest plots of standardised mean difference of reactive hyperaemia in septic patients and controls with 
cardiovascular disease
 –10 –5 0 5 10
                                         Sepsis   Control with CV risk control
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but the magnitude of the effect was inconsistent 
across studies. Measures of vascular reactivity in 
early sepsis were lower in non survivors, but the 
data were less reliable. There was insufficient data 
to quantitatively evaluate the relationship between 
vascular reactivity and development of MOF.
This systematic review is based on a limited 
number of single site studies using four different 
measurement methods, many with small sample 
sizes. There are major differences in the vascular 
beds explored by the studies – laser Doppler flow-
metry evaluates microvascular blood flow, venous 
air and mercury strain gauge plethysmography 
allows measurement of total forearm blood flow, 
flow-mediated vasodilatation (FMD) reflects the 
bioavailability of endothelium-derived NO in the 
brachial artery, and RH-PAT measures fingertip 
reactive hyperaemia. An ideal method of testing 
vascular reactivity should allow quantification of 
both endothelium-dependent and -independent 
vasodilatation. Such methods exist but are in-
vasive and require intraarterial or iontophoretic 
provocation agent administration, which makes 
them difficult to use in critically ill patients. The 
only study using the gold standard research tool 
[32] – vascular occlusion plethysmography with 
pharmacological provocation – found no differ-
ence in endothelium-dependent vasodilation in 
patients with septic shock compared with volun-
teers. Unfortunately, this study had insufficient 
numerical data to be included in this meta-anal-
ysis. Similar results were obtained in studies [16] 
using measurement of hyperaemia provoked by 
acetylcholine iontophoresis with laser Doppler 
flowmetry. Most functional methods used mea-
sure a composite value of different mechanisms 
producing vasodilatation only one of which is 
bioavailability of NO and is related to endothelial 
function; therefore, it is likely that the consistent 
decrease of vascular reactivity found in sepsis is 
due to mechanisms other than endothelial dys-
function. Methodological heterogeneity shown by 
the variety of measurement protocols and sites 
used in the studies makes findings difficult to 
generalise.
When comparing the populations from pub-
lished studies of sepsis epidemiology [33], stud-
ies in this review tended to include patients from 
the same age group but with considerably greater 
disease severity. Septic patients with a variety of 
clinical characteristics and in a variety of settings 
exhibited a decrease in vascular reactivity across 
studies with the exception of studies that used 
a comparison group consisting of patients with se-
vere cardiovascular disease. Patients after cardiac 
and vascular surgery used as comparators have 
factors other than sepsis, which can influence vas-
cular reactivity and are known to have a particu-
larly high incidence of decreased vascular reactiv-
ity [34]. On the other hand, patients with sepsis 
are often elderly, have advanced atherosclerosis, 
use statins, have hyperlipidaemia, hypertension, 
and diabetes, are smokers or obese, and consti-
tute a high-risk group for vascular dysfunction. 
Only one study in this review enrolled exclusively 
young patients and another two corrected for co-
morbidity using the Charlson index. The extent to 
which comorbidities contribute to results of vas-
cular reactivity tests in septic patients is yet to be 
established.
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A minority of studies examined changes in vas-
cular reactivity in the context of progression of 
MOF or mortality. Association with these critical 
outcomes was not convincing. The reason for the 
weak of association could be that the pathophys-
iological mechanisms tested in vascular beds of 
the forearm do not directly reflect changes in the 
vasculature involved in splanchnic perfusion. The 
timing of measurement of endothelial function in 
the course of sepsis is possibly very relevant. The 
studies in this review evaluate endothelial func-
tion early, within the first 24–48 h of admission, 
and seek to correlate the extent of changes in vas-
cular reactivity to the progression of sepsis. There 
might be temporal variation in onset of vascular 
changes in septic patients, as shown by Hartl et al. 
[18], who found loss of post-ischaemic hyperae-
mia to occur on day 8 to 10 from admission in 
parallel with worsening clinical course and poor 
prognosis. Longitudinal studies documenting en-
dothelial function from admission to discharge 
or death would be important to clarify the time 
course of vascular reactivity and its relation to 
MOF and mortality.
Experimental and animal data show that sep-
sis causes endothelial dysfunction, but finding 
a surrogate marker of endothelial health for use 
in patients with sepsis is challenging. Other than 
measurable physiological responses, circulating 
biomarkers have been investigated in studies. A 
previous systematic review addressing clinical 
utility of biomarkers of endothelial activation in 
sepsis similarly to our review found a correlation 
between various endothelium-derived molecules 
and the presence of sepsis, but correlation with 
clinically important outcomes was not consistent 
[7]. The reason for inconsistency across studies 
using different markers has been postulated to 
be lack of method standardisation, and unclear 
threshold values and receiver operator character-
istics.
This systematic review has several potential 
limitations. Although we tried to identify all eli-
gible studies by searching three citation databas-
es, only publications in English could be included. 
There might be studies that have been missed. An 
important limitation is the small number of includ-
ed studies; therefore, reliable conclusions could 
not be drawn about the association between vas-
oreactivity and development of MOF. Most of the 
studies were of low methodological quality with a 
high possibility of random error. Subjects included 
in both control and sepsis groups were diverse in 
terms of age, sex, and disease severity, with multi-
ple potential confounders. As none of the studies 
used random sampling, selection bias is also like-
ly. However, gaps in current knowledge identified 
by our study could be useful for further research 
in this area.
Before better conclusions can be drawn the most 
important first step would be consensus regarding 
the most suitable method and measurement protocol 
of vascular reactivity and especially endothelium-de-
pendent vasodilatation for critically ill patients.
In conclusion, from the studies included in this 
review there is evidence of moderate strength that 
vascular reactivity is impaired in septic patients, 
but there is insufficient evidence to suggest that 
that it is a consequence of endothelial dysfunc-
tion or is convincingly related to clinical outcomes.
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